Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) 2% - Seite 3

Do not:

• Apply PENNSAID 2% to open wounds.
  
  
• Shower for at least 30 minutes after applying PENNSAID 2%. 
  
  
• Wear clothing over the PENNSAID 2% treated knee until the treated knee is dry.
  
  

Protect treated knee(s) from natural or artificial sunlight.

Protect treated knee(s) from sunlight (real and tanning booths).

Topicals, such as sunscreen and bug repellent, should not be used until after PENNSAID 2% treated knee(s) are completely dry.

Do not use with oral NSAIDs unless your doctor says it is OK and you have lab tests to check your progress.

There is no consistent evidence that regular use of aspirin lessens the increased risk of serious heart events, such as heart clotting, heart attack and stroke associated with NSAID use. As with all NSAIDs, regular administration of PENNSAID 2% and aspirin is not generally recommended because of the potential of increased risks.

ADVERSE REACTIONS

• The most common adverse events in a phase 2 clinical trial of PENNSAID 2% were application site reactions, such as dryness (22%), peeling (7%), redness (4%), itching (2%), pain (2%), skin hardening (2%), rash (2%) and scabbing ( < 1%). Other adverse reactions occurring in > 1% of patients receiving PENNSAID 2% included bladder infection (3%), bruising (2%), sinus congestion (2%) and nausea (2%).

USE IN SPECIFIC POPULATIONS

• PENNSAID 2% should not be used in pregnant woman or in women who are breastfeeding and is not approved for use in children. 

For more information on PENNSAID 2%, please see the Medication Guide and Full Prescribing Information, available at www.PENNSAID.com.

About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.